Ainos, Inc. Files 8-K Report

TL;DR

Ainos, Inc. (AIMD) filed an 8-K on 9/5, check for updates.

AI Summary

On September 5, 2025, Ainos, Inc. filed an 8-K report detailing "Other Events" and "Financial Statements and Exhibits." The filing was made public on September 8, 2025. The company, formerly known as Amarillo Biosciences Inc., is incorporated in Texas and has its principal business address in San Diego, California.

Why It Matters

This 8-K filing serves as an official notification to the SEC and investors about significant corporate events or financial updates for Ainos, Inc.

Risk Assessment

Risk Level: low — This filing is a routine 8-K report and does not appear to contain any immediately alarming or significant negative news.

Key Players & Entities

• Ainos, Inc. (company) — Registrant
• September 5, 2025 (date) — Date of earliest event reported
• September 8, 2025 (date) — Filing date
• Amarillo Biosciences Inc. (company) — Former company name
• Texas (jurisdiction) — State of incorporation
• San Diego, CA (location) — Business address

FAQ

Key Financial Figures

• $0.01 — ch registered Common Stock, par value $0.01 per share AIMD The Nasdaq Stock Mar
• $1,353,197 — ng an aggregate offering price of up to $1,353,197 from time to time through the Placement
• $1,840,350 — offered and sold under the Agreement to $1,840,350. Prior to the date hereof, the Company
• $1,840,337 — aggregate sales price of approximately $1,840,337 under the Agreement. On September 5, 20
• $874,496 — under the Agreement for an aggregate of $874,496 of additional shares of Common Stock.

Filing Documents

• form8-k.htm (8-K) — 42KB
• ex5-1.htm (EX-5.1) — 20KB
• ex5-1_001.jpg (GRAPHIC) — 11KB
• 0001493152-25-012781.txt ( ) — 286KB
• aimd-20250905.xsd (EX-101.SCH) — 4KB
• aimd-20250905_def.xml (EX-101.DEF) — 26KB
• aimd-20250905_lab.xml (EX-101.LAB) — 36KB
• aimd-20250905_pre.xml (EX-101.PRE) — 25KB
• form8-k_htm.xml (XML) — 5KB

01 Other Events

Item 8.01 Other Events. As previously reported, on May 31, 2024, Ainos, Inc. (the "Company") entered into an At The Market Offering Agreement (the "Agreement") with H.C. Wainwright & Co., LLC as placement agent (the "Placement Agent") to offer and sell shares of its common stock, par value $0.01 per share ("Common Stock"), having an aggregate offering price of up to $1,353,197 from time to time through the Placement Agent. On July 11, 2024, the Company filed a prospectus supplement under the Agreement to increase the aggregate offering price of Common Stock to be offered and sold under the Agreement to $1,840,350. Prior to the date hereof, the Company sold shares of Common Stock having an aggregate sales price of approximately $1,840,337 under the Agreement. On September 5, 2025, the Company filed a prospectus supplement under the Agreement for an aggregate of $874,496 of additional shares of Common Stock. A copy of the legal opinion of Lucosky Brookman LLP, relating to the validity of the shares in connection with the Agreement is filed as Exhibit 5.1 to this Current Report on Form 8-K and is incorporated herein by reference. Item 9.01 Financial Statement and Exhibits (d) Exhibits. Exhibit No. Description 5.1 Opinion of Lucosky Brookman LLP. 23.1 Consent of Lucosky Brookman LLP (included in Exhibit 5.1) 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Ainos, Inc. Date: September 8, 2025 By: /s/ Chun-Hsien Tsai Name: Chun-Hsien Tsai Title: Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR